Literature DB >> 26951483

Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.

Rui Li1, Tristan S Maurer2, Kevin Sweeney3, Hugh A Barton4.   

Abstract

The physiologically based pharmacokinetic (PBPK) model for liver transporter substrates has been established previously and used for predicting drug-drug interactions (DDI) and for clinical practice guidance. So far, nearly all the published PBPK models for liver transporter substrates have one or more hepatic clearance processes (i.e., active uptake, passive diffusion, metabolism, and biliary excretion) estimated by fitting observed systemic data. The estimated hepatic clearance processes are then used to predict liver concentrations and DDI involving either systemic or liver concentration. However, the accuracy and precision of such predictions are unclear. In this study, we try to address this question by using the PBPK model to generate simulated compounds for which we know both systemic and liver profiles. We then developed an approach to assess the accuracy and precision of predicted liver concentration. With hepatic clearance processes estimated using plasma data, model predictions of liver are typically accurate (i.e., true value is bounded by predicted maximum and minimum); however, only for a few compounds are predictions also precise. The results of the current study indicate that extra attention is required when using the current PBPK approach to predict liver concentration and DDI for transporter substrates dependent upon liver concentrations.

Keywords:  identifiability analysis; liver transporter; physiologically based pharmacokinetic (PBPK) model

Mesh:

Substances:

Year:  2016        PMID: 26951483      PMCID: PMC5256613          DOI: 10.1208/s12248-016-9895-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  14 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  J Pharm Sci       Date:  2006-06       Impact factor: 3.534

3.  DAISY: a new software tool to test global identifiability of biological and physiological systems.

Authors:  Giuseppina Bellu; Maria Pia Saccomani; Stefania Audoly; Leontina D'Angiò
Journal:  Comput Methods Programs Biomed       Date:  2007-08-20       Impact factor: 5.428

Review 4.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

5.  Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.

Authors:  Paul D Martin; Mike J Warwick; Aaron L Dane; Charlie Brindley; Tracy Short
Journal:  Clin Ther       Date:  2003-10       Impact factor: 3.393

6.  Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.

Authors:  Takao Watanabe; Hiroyuki Kusuhara; Kazuya Maeda; Yoshihisa Shitara; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2008-11-10       Impact factor: 4.030

Review 7.  Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results.

Authors:  R C Spear; F Y Bois
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

8.  Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry.

Authors:  M Rowland
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-10

9.  Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.

Authors:  R Li; H A Barton; T S Maurer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-12-10

10.  Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.

Authors:  R H Rose; S Neuhoff; K Abduljalil; M Chetty; A Rostami-Hodjegan; M Jamei
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-07-09
View more
  4 in total

1.  Estimation of the Effect of OAT2-Mediated Active Uptake on Meloxicam Exposure in the Human Liver.

Authors:  Rui Li; Sumathy Mathialagan; Jonathan J Novak; Heather Eng; Keith Riccardi; John Litchfield
Journal:  AAPS J       Date:  2020-01-03       Impact factor: 4.009

2.  Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.

Authors:  K Yang; C Battista; J L Woodhead; S H Stahl; J T Mettetal; P B Watkins; S Q Siler; B A Howell
Journal:  Clin Pharmacol Ther       Date:  2017-02-17       Impact factor: 6.875

3.  Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity.

Authors:  Christina Battista; Kyunghee Yang; Simone H Stahl; Jerome T Mettetal; Paul B Watkins; Scott Q Siler; Brett A Howell
Journal:  Toxicol Sci       Date:  2018-11-01       Impact factor: 4.849

4.  Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.

Authors:  Daniel Scotcher; Nicola Melillo; Sirisha Tadimalla; Adam S Darwich; Sabina Ziemian; Kayode Ogungbenro; Gunnar Schütz; Steven Sourbron; Aleksandra Galetin
Journal:  Mol Pharm       Date:  2021-07-20       Impact factor: 4.939

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.